BRIEF: Teva launches generic Niaspan [Globes, Tel Aviv, Israel]
(Globes (Tel Aviv) Via Acquire Media NewsEdge) Sept. 22--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic Niaspan in the US. Niaspan had $1.12 billion in annual sales in the US, according to IMS data as of June 30, 2013. Teva will sell generic Niaspan in 500, 750, and 1000 milligram tablets. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Brand Niaspan is sold by AbbVie Inc. (Nasdaq: ABBV) and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
(c)2013 the Globes (Tel Aviv, Israel)
Visit the Globes (Tel Aviv, Israel) at www.globes.co.il/serveen/globes/nodeview.asp?fid=942
Distributed by MCT Information Services
[ Back To Technology News's Homepage ]